Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Jennifer M. Finan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7706-1643; OpenAlex author ID A5032207472. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 8

  1. Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design. Co-author DOI 10.1016/j.canlet.2026.218864↗
  2. The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1136/jitc-2025-sitc2025.1250↗
  3. Challenges and caveats in manipulating extracellular vesicle secretion from pancreatic cancer cells. Co-author DOI 10.1080/15384047.2025.2569946↗
  4. Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma First author DOI 10.1101/2025.02.07.632847↗
  5. HuR-Regulated Extracellular Vesicles Promote Endothelial Cell Remodeling in Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-25-0355↗
  6. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Co-author DOI 10.1080/15384047.2024.2421584↗
  7. Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. Co-author DOI 10.1093/narcan/zcad016↗
  8. Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-21-0601↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonathan Robert Brody · 7 shared papers, 2023–2026 · strength 1.80
  2. Rosalie C. Sears · 6 shared papers, 2023–2026 · strength 1.26
  3. Yifei Guo · 4 shared papers, 2023–2026 · strength 0.81
  4. Grace A. McCarthy · 4 shared papers, 2023–2026 · strength 0.78
  5. Zheng Xia · 4 shared papers, 2022–2026 · strength 0.77
  6. Aaron J. Grossberg · 3 shared papers, 2025–2026 · strength 0.69
  7. Kevin Hawthorne · 3 shared papers, 2025–2026 · strength 0.64
  8. Canping Chen · 3 shared papers, 2025–2026 · strength 0.64
  9. Katelyn T. Byrne · 2 shared papers, 2025–2026 · strength 0.48
  10. Lisa M. Coussens · 2 shared papers, 2025–2026 · strength 0.43
  11. Katie E. Blise · 2 shared papers, 2025–2026 · strength 0.43
  12. Robert L Eil · 2 shared papers, 2025–2026 · strength 0.43
  13. Kyle P. Gribbin · 1 shared paper, 2026 · strength 0.26
  14. Adel Kardosh · 1 shared paper, 2026 · strength 0.26
  15. Teresa A Zimmers · 1 shared paper, 2026 · strength 0.26
  16. Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.26
  17. Charles D. Lopez · 1 shared paper, 2026 · strength 0.26
  18. Katherine R. Pelz · 1 shared paper, 2026 · strength 0.22
  19. Vidhi M. Shah · 1 shared paper, 2026 · strength 0.22
  20. Emanuel F. Petricoin · 1 shared paper, 2025 · strength 0.22
  21. Margaret E. Haerr · 1 shared paper, 2025 · strength 0.22
  22. Gordon Brent Mills · 1 shared paper, 2024 · strength 0.19
  23. Alex O. Haber · 1 shared paper, 2024 · strength 0.19
  24. Aditi Jain · 1 shared paper, 2023 · strength 0.17
  25. Alexander Savio Ramos Guimaraes · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.